WO2011118982A3 - 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법 - Google Patents

융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법 Download PDF

Info

Publication number
WO2011118982A3
WO2011118982A3 PCT/KR2011/002002 KR2011002002W WO2011118982A3 WO 2011118982 A3 WO2011118982 A3 WO 2011118982A3 KR 2011002002 W KR2011002002 W KR 2011002002W WO 2011118982 A3 WO2011118982 A3 WO 2011118982A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
antigens
fusion polypeptide
antigen
present
Prior art date
Application number
PCT/KR2011/002002
Other languages
English (en)
French (fr)
Other versions
WO2011118982A2 (ko
Inventor
안웅식
배수미
Original Assignee
주식회사 진진바이오
다이아텍코리아 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진진바이오, 다이아텍코리아 주식회사 filed Critical 주식회사 진진바이오
Priority to JP2013501189A priority Critical patent/JP2013527752A/ja
Publication of WO2011118982A2 publication Critical patent/WO2011118982A2/ko
Publication of WO2011118982A3 publication Critical patent/WO2011118982A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541—Double or second antibody, i.e. precipitating antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Abstract

본 발명은 융합 폴리펩타이드 HPV 항원을 이용한 ＨＰＶ 항체 스크리닝 방법으로서, N 말단에 글루타티온 S-트랜스퍼라제(Glutathione S-transferase, GST)의 아미노산 서열 또는 이의 활성단편 C 말단에 시미안 바이러스 40 대형 T 항원(simian virus 40 large T-antigen)의 아미노산 서열 또는 이의 활성단편 및 HPV 6 L1 항원, HPV11 L1 항원, HPV16 L1 항원 및 HPV18 L1 항원으로 구성된 군으로부터 선택된 HPV L1 항원의 아미노산 서열 또는 이의 활성단편을 포함하는 융합 폴리펩타이드, 상기 융합 폴리펩타이드 HPV 항원을 이용하여 시료 내 HPV 항체를 검출하는 방법 및 상기 융합 폴리펩타이드 HPV 항원을 포함하는 비드 어레이용 HPV 항체 검출 키트에 관한 것이다. 본 발명을 이용하면 HPV 항체에 특이적으로 결합할 수 있는 활성에 영향을 미치지 않으면서도 재조합 HPV 항원을 고순도로 분리, 정제하고 비드 어레이용 비드에 효과적으로 균일하게 부착시킬 수 있어 높은 민감도 및 정확도로 시료 내 HPV 6, 11, 16 및 18 항체를 복합적으로 검출할 수 있다. 항체 역가를 측정하여 HPV 백신의 접종시기를 결정하는데 활용될 수 있고, 백신 접종 후 방어 기간의 측정 등에 활용 가능하다.
PCT/KR2011/002002 2010-03-23 2011-03-23 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법 WO2011118982A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013501189A JP2013527752A (ja) 2010-03-23 2011-03-23 融合ポリペプチドｈｐｖ抗原を用いたｈｐｖ抗体スクリーニング方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100025690 2010-03-23
KR10-2010-0025690 2010-03-23

Publications (2)

Publication Number Publication Date
WO2011118982A2 WO2011118982A2 (ko) 2011-09-29
WO2011118982A3 true WO2011118982A3 (ko) 2012-04-05

Family

ID=44673759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002002 WO2011118982A2 (ko) 2010-03-23 2011-03-23 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법

Country Status (3)

Country Link
JP (1) JP2013527752A (ko)
KR (1) KR101340649B1 (ko)
WO (1) WO2011118982A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012350229B2 (en) * 2011-12-09 2018-03-22 Institut Pasteur Multiplex immuno screening assay
KR101347288B1 (ko) * 2012-05-18 2014-01-06 안웅식 융합 폴리펩타이드 ｈｐｖ 항원을 이용한 ｈｐｖ 항체 스크리닝 키트
CN106662579A (zh) * 2014-04-28 2017-05-10 代表亚利桑那州立大学的亚利桑那校董会 用于hpv‑相关病症的新方法、生物试验和生物标记物
CN108872596A (zh) * 2018-07-05 2018-11-23 重庆巴而思生物科技有限公司 一种hpv16 l1抗体的elisa检测试剂盒
KR20220155712A (ko) 2021-05-17 2022-11-24 (주)베데스다 인유두종 바이러스 및 자궁경부암 감지용 다클론성 항체 및 이의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049329A1 (en) * 2006-10-19 2008-05-02 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Hpv antigen fusion protein vaccine compositions and uses thereof
WO2009124932A1 (en) * 2008-04-08 2009-10-15 DKFZ Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting the hpv-e6 oncoprotein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049329A1 (en) * 2006-10-19 2008-05-02 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Hpv antigen fusion protein vaccine compositions and uses thereof
WO2009124932A1 (en) * 2008-04-08 2009-10-15 DKFZ Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting the hpv-e6 oncoprotein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACHOUR, M. ET AL.: "Production of recombinant proteins GST L1, E6 and E7 tag HPV 16 for antibody detection of Tunisian cervical cancer patients.", AFRICAN JOURNAL OF BIOTECHNOLOGY., vol. 8, no. 3, 2009, pages 369 - 374 *
PETER SEHR ET AL.: "A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology.", JOURNAL OF IMMUNOLOGICAL METHODS., vol. 23, no. ISSUES, 2001, pages 153 - 162 *
PETER SEHR ET AL.: "HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.", JOURNAL OF VIROLOGICAL METHODS., vol. 106, no. 1, 2002, pages 61 - 70, XP055234184, DOI: doi:10.1016/S0166-0934(02)00134-9 *

Also Published As

Publication number Publication date
JP2013527752A (ja) 2013-07-04
WO2011118982A2 (ko) 2011-09-29
KR20110106826A (ko) 2011-09-29
KR101340649B1 (ko) 2014-01-03

Similar Documents

Publication Publication Date Title
KR102443389B1 (ko) Sarsr-cov에 대한 항체의 검출
Singh et al. Development of a monoclonal antibody based competitive-ELISA for detection and titration of antibodies to peste des petits ruminants (PPR) virus
CN108107217B (zh) 猪瘟病毒截短e2蛋白及其应用
Choi et al. Antigenic and immunogenic investigation of the virulence motif of the Newcastle disease virus fusion protein
WO2008027942A3 (en) Combination hepatitis c virus antigen and antibody detection method
WO2011118982A3 (ko) 융합 폴리펩타이드 hpv 항원을 이용한 ｈｐｖ 항체 스크리닝 방법
TW201233686A (en) Monoclonal antibody recognizing human papillomavirus (HPV) L2 protein and method for measuring HPV-neutralizing antibody titer using the same
JP2008503720A (ja) ハンタウイルス感染の診断のための方法および試薬
CN108473540B (zh) 突变的hev多肽及其用于测定抗hev抗体的用途
JP2010539161A5 (ko)
Zhao et al. Engineered recombinant protein products of the avian paramyxovirus type-1 nucleocapsid and phosphoprotein genes for serological diagnosis
JP2014524583A5 (ko)
WO2007008092A3 (en) Diagnostic kit for the examination of animal sera for the presence of anti-rhd antibodies and a diagnostic kit for detecting the rhd virus
WO2009151697A3 (en) Compositions and processes relating to human bocavirus
ES2375095T3 (es) Utilización del péptido sintético derivado de la proteína zebra para el diagnóstico in vivo de la reactivación del virus de epstein-barr (ebv).
JP5712513B2 (ja) ヒトサイトメガロウイルス感染の検出方法
US20170121373A1 (en) Expression and conformational analysis of engineered influenza hemagglutinin
JP6908299B2 (ja) サンプル中のフラビウイルスに特異的なＩｇＭ抗体の検出方法
RU2014114532A (ru) Способ измерения антитела против wt1
WO2016179099A4 (en) Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
JP2009525741A5 (ja) HERV−W干渉群に属するウィルスの包膜とhASCT受容体との間の相互作用に必要なペプチド領域からなるペプチド
US20230266336A1 (en) Coronavirus Assays, Diagnostic Methods, Treatment Methods, and Compositions Related Thereto
Budama-Kilinc et al. The development of a universally conserved m2e and hemagglutinin peptide-based elisa method against influenza a
Harer et al. Novel Coronavirus disease 2019 (COVID-19) Current update: perspective on epidemiology, diagnosis, drug Targets and vaccines
WO2009016839A1 (ja) 抗原濃度測定法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11759731

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013501189

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2447/MUMNP/2012

Country of ref document: IN

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/01/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11759731

Country of ref document: EP

Kind code of ref document: A2